心型脂肪酸结合蛋白(H-FABP)活性蛋白
Active Heart-type Fatty Acid Binding Protein (H-FABP)
MDGI; FABP11; H-FABP; O-FABP; Hfabp; FABP3; Fatty Acid Binding Protein 3, Muscle And Heart; Mammary Derived Growth Inhibitor; Fatty Acid Binding Protein 11; Muscle fatty acid-binding protein; Heart-ty
- 编号APB243Hu01
- 物种Homo sapiens (Human,人) 相同的名称,不同的物种。
- 缓冲液成份20mM Tris, 150mM NaCl缓冲液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性状冻干粉
- 纯度> 95%
- 等电点6.6
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1152 ¥ 2880 ¥ 5760 ¥ 17280 ¥ 43200
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
活性实验
Fatty Acid Binding Protein 3, Muscle And Heart (FABP3) also known as mammary-derived growth inhibitor is a protein that in humans is encoded by the FABP3 gene. FABP3 is a small cytoplasmic protein (15kDa) released from cardiac myocytes following an ischemic episode. It is involved in active fatty acid metabolism where it transports fatty acids from the cell membrane to mitochondria for oxidation. Besides, Fatty Acid Binding Protein 3, Muscle And Heart (FABP3) has been identified as an interactor of SOD1, thus a binding ELISA assay was conducted to detect the interaction of recombinant human FABP3 and recombinant human SOD1. Briefly, FABP3 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to SOD1-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FABP3 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of FABP3 and SOD1 was shown in Figure 1, and this effect was in a dose dependent manner.
Figure. The binding activity of FABP3 with SOD1.
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
增值服务
相关产品
编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) |
RPB243Hu01 | 心型脂肪酸结合蛋白(H-FABP)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB243Hu01 | 心型脂肪酸结合蛋白(H-FABP)活性蛋白 | Cell culture; Activity Assays. |
EPB243Hu61 | 心型脂肪酸结合蛋白(H-FABP)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB243Hu01 | 心型脂肪酸结合蛋白(H-FABP)多克隆抗体 | WB; IHC; ICC; IP; FCM |
LAB243Hu81 | 心型脂肪酸结合蛋白(H-FABP)多克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. |
LAB243Hu71 | 心型脂肪酸结合蛋白(H-FABP)多克隆抗体(生物素标记) | WB; IHC; ICC. |
MAB243Hu23 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | WB; IHC; ICC; IP. |
MAB243Hu24 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | WB; IHC; ICC; IP. |
MAB243Hu25 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | WB; IHC; ICC; IP. |
MAB243Hu27 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | WB; IHC; ICC; IP. |
MAB243Hu21 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | WB; IHC; ICC; IP. |
MAB243Hu22 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | WB; IHC; ICC; IP. |
MAB243Hu29 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | WB; IHC; ICC; IP. |
FAB243Hu02 | 抗心型脂肪酸结合蛋白(H-FABP)单克隆抗体 | Flow cytometry. |
LAB243Hu72 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体(生物素标记) | WB; IHC; ICC. |
LAB243Hu82 | 心型脂肪酸结合蛋白(H-FABP)单克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. |
HEB243Hu | 心型脂肪酸结合蛋白(H-FABP)检测试剂盒(酶联免疫吸附试验法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEB243Hu | 心型脂肪酸结合蛋白(H-FABP)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB243Hu | 心型脂肪酸结合蛋白(H-FABP)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
KSB243Hu01 | 心型脂肪酸结合蛋白(H-FABP)检测试剂盒DIY材料(酶联免疫吸附试验法) | 自己动手制作ELISA试剂盒的主要材料 |
参考文献
杂志 | 参考文献 |
Molecular Medicine Reports | Protective effects of N (2)‑L‑alanyl‑L‑glutamine mediated by the JAK2/STAT3 signaling pathway on myocardial ischemia reperfusion [Pubmed:29393473] |
Oncology Letters | Hydrogen‑rich solution attenuates myocardial injury caused by cardiopulmonary bypass in rats via the Janus‑activated kinase 2/signal transducer and activator of … [Pubmed:29928398] |
FASEB Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure [Pubmed: 30230922] |